Dopaminagonists and fibrotic valvular heart disease: Further considerations
Identifieur interne : 000435 ( France/Analysis ); précédent : 000434; suivant : 000436Dopaminagonists and fibrotic valvular heart disease: Further considerations
Auteurs : Olivier Rascol [France] ; Atul Pathak [France] ; Haleh Bagheri [France] ; Jean-Louis Montastruc [France]Source :
- Movement Disorders [ 0885-3185 ] ; 2004-12.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Dopamine Agonists, Pergolide.
- chemically induced : Fibrosis, Heart Valve Diseases.
- drug therapy : Parkinson Disease.
- Humans.
Abstract
Companion letters have been published in this issue of Movement Disorders: Chaudhuri et al., pp 1522–1523, and Horowski et al., pp 1523–1524.
Url:
DOI: 10.1002/mds.20328
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 003415
- to stream Istex, to step Curation: 003415
- to stream Istex, to step Checkpoint: 002719
- to stream PubMed, to step Corpus: 003209
- to stream PubMed, to step Curation: 003209
- to stream PubMed, to step Checkpoint: 003484
- to stream Ncbi, to step Merge: 001079
- to stream Ncbi, to step Curation: 001079
- to stream Ncbi, to step Checkpoint: 001079
- to stream Main, to step Merge: 005696
- to stream Main, to step Curation: 003D38
- to stream Main, to step Exploration: 003D38
- to stream France, to step Extraction: 000435
Links to Exploration step
ISTEX:22C25F219A69FFC6A0EAEB51AFBAF3C8E55DB250Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopaminagonists and fibrotic valvular heart disease: Further considerations</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><country>France</country><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Pathak, Atul" sort="Pathak, Atul" uniqKey="Pathak A" first="Atul" last="Pathak">Atul Pathak</name></author><author><name sortKey="Bagheri, Haleh" sort="Bagheri, Haleh" uniqKey="Bagheri H" first="Haleh" last="Bagheri">Haleh Bagheri</name></author><author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:22C25F219A69FFC6A0EAEB51AFBAF3C8E55DB250</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/mds.20328</idno><idno type="url">https://api.istex.fr/document/22C25F219A69FFC6A0EAEB51AFBAF3C8E55DB250/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003415</idno><idno type="wicri:Area/Istex/Curation">003415</idno><idno type="wicri:Area/Istex/Checkpoint">002719</idno><idno type="wicri:doubleKey">0885-3185:2004:Rascol O:dopaminagonists:and:fibrotic</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15515031</idno><idno type="wicri:Area/PubMed/Corpus">003209</idno><idno type="wicri:Area/PubMed/Curation">003209</idno><idno type="wicri:Area/PubMed/Checkpoint">003484</idno><idno type="wicri:Area/Ncbi/Merge">001079</idno><idno type="wicri:Area/Ncbi/Curation">001079</idno><idno type="wicri:Area/Ncbi/Checkpoint">001079</idno><idno type="wicri:doubleKey">0885-3185:2004:Rascol O:dopaminagonists:and:fibrotic</idno><idno type="wicri:Area/Main/Merge">005696</idno><idno type="wicri:Area/Main/Curation">003D38</idno><idno type="wicri:Area/Main/Exploration">003D38</idno><idno type="wicri:Area/France/Extraction">000435</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Dopaminagonists and fibrotic valvular heart disease: Further considerations</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><country wicri:rule="url">France</country><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Center and Pharmacovigilance Center, Toulouse University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Pathak, Atul" sort="Pathak, Atul" uniqKey="Pathak A" first="Atul" last="Pathak">Atul Pathak</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Center and Pharmacovigilance Center, Toulouse University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Bagheri, Haleh" sort="Bagheri, Haleh" uniqKey="Bagheri H" first="Haleh" last="Bagheri">Haleh Bagheri</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Center and Pharmacovigilance Center, Toulouse University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Center and Pharmacovigilance Center, Toulouse University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-12">2004-12</date><biblScope unit="vol">19</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1524">1524</biblScope><biblScope unit="page" to="1525">1525</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">22C25F219A69FFC6A0EAEB51AFBAF3C8E55DB250</idno><idno type="DOI">10.1002/mds.20328</idno><idno type="ArticleID">MDS20328</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine Agonists (adverse effects)</term><term>Fibrosis (chemically induced)</term><term>Heart Valve Diseases (chemically induced)</term><term>Humans</term><term>Parkinson Disease (drug therapy)</term><term>Pergolide (adverse effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine Agonists</term><term>Pergolide</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Fibrosis</term><term>Heart Valve Diseases</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="fr">Companion letters have been published in this issue of Movement Disorders: Chaudhuri et al., pp 1522–1523, and Horowski et al., pp 1523–1524.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Midi-Pyrénées</li></region><settlement><li>Toulouse</li></settlement><orgName><li>Université Toulouse III - Paul Sabatier</li><li>Université de Toulouse</li></orgName></list><tree><country name="France"><region name="Midi-Pyrénées"><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></region><name sortKey="Bagheri, Haleh" sort="Bagheri, Haleh" uniqKey="Bagheri H" first="Haleh" last="Bagheri">Haleh Bagheri</name><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><name sortKey="Pathak, Atul" sort="Pathak, Atul" uniqKey="Pathak A" first="Atul" last="Pathak">Atul Pathak</name><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000435 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000435 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:22C25F219A69FFC6A0EAEB51AFBAF3C8E55DB250
|texte= Dopaminagonists and fibrotic valvular heart disease: Further considerations
}}
| This area was generated with Dilib version V0.6.23. |  |